Making Sense of Intratumor Genetic Heterogeneity: Altered Frequency of Androgen Receptor CAG Repeat Length Variants in Breast Cancer Tissues

Human Mutation

Volumn 34, Issue 4, 2013, Pages 610-618

  Gottlieb, Bruce ^a,b,c   Alvarado, Carlos ^a   Wang, Chunlin ^d   Gharizadeh, Baback ^d   Babrzadeh, Farbod ^d   Richards, Brent ^a,b   Batist, Gerald ^a,b,c   Basik, Mark ^b,c   Beitel, Lenore K ^a,b,c   Trifiro, Mark ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Breast cancer; CAG repeat; Intratumor genetic heterogeneity

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CAG REPEAT; CANCER RISK; CANCER TISSUE; CONTROLLED STUDY; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LEUKOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STUDENT T TEST;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC VARIATION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEATS;

EID: 84875494277     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22287     Document Type: Article

References (51)

1. n repeat. J Androl 33:210-215.
2. Alvarado C, Beitel LK, Sircar K, Aprikian A, Trifiro M, Gottlieb B. 2005. Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res 65:8514-8518.
3. Beilin J, Ball EM, Favaloro JM, Zajac JD. 2000. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. Mol Endocrinol 25:85-96.
4. Bertos NR, Park M. 2011. Breast cancer-one term, many entities. J Clin Invest 121:3789-3796.
5. Bissel MJ, Hines WC. 2011. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17:320-329.
6. Brockman W, Alvarez P, Young S, Garber M, Giannoukos G, Lee WL, Russ C, Lander ES, Nusbaum C, Jaffe DB. 2008. Quality cores and SNP detection in sequencing-by-synthesis systems. Genome Res 18:763-770.
7. Chaffer CL, Weinberg RA. 2011. A perspective on cancer cell metastasis. Science 331:1559-1564.
8. Clemons M, Goss P. 2001. Estrogen and the risk of breast cancer. N Engl J Med 344:276-285.
9. Cooke SL, Temple J, MacArthur S, Zahra MA, Tan LT, Crawford RAF, Ng CK, Jimenez-Linan M, Sala E, Brenton JD. 2011. Intra-tumor genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. Br J Cancer 104:361-368.
10. Galvan A, Ioannidis JPA, Dragani TA. 2010. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 28:132-141.
11. Geraci G, D'Elia I, del Gaudio R, Di Giaimo R. 2010. Evidence of genetic instability in tumors and normal nearby tissues. PLoS ONE 5:e9343.
12. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892.
13. Giguère Y, Dewailly E, Brisson J, Ayotte P, Laflamme N, Demers A, Forest VI, Dodin S, Robert J, Rousseau F. 2001. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 61:5869-5874.
14. Gottlieb B, Beitel LK, Alvarado C, Trifiro M. 2010. Selection and mutation in the "new" genetics: an emerging hypothesis. Hum Genet 127:491-501.
15. Gottlieb B, Beitel LK, Wu J, Elhaji YA, Trifiro M. 2004. Nuclear receptors and disease: androgen receptor. Essays Biochem 40:121-136.
16. Haber DA, Settleman J. 2007. Cancer: drivers and passengers. Nature 446:145-146.
17. Hao Y, Montiel R, Li B, Huang E, Zeng L, Huang Y. 2010. Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 124:815-820.
18. Heppner GH, Miller BE. 1983. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 2:5-23.
19. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Colke K, Marotti JD, Hanikson SE, Colditz GA, Tamimi RM. 2011. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17:1867-1874.
20. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. 2000. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9:267-274.
21. Kaiser J. 2011. Combining targeted drugs to stop resistant tumors. Science 331:1542-1545.
22. n-expanded neuronopathies. Hum Mol Genet 4:523-527.
23. Korkaya H, Liu S, Wicha MS. 2011. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121:3804-3809.
24. Kotsopoulos J, Narod SA. 2011. Androgens and breast cancer. Steroids 77:1-9.
25. Kozlowski P, de Mezer M, Krzyzosiak WJ. 2010. Trinucleotide repeats in human genome and exome. Nucleic Acids Res 18:4027-4039.
26. Lee J-M, Pinto RM, Gillis T, St. Clare JC, Wheeler VC. 2011. Quantification of age-dependant somatic CAG repeat instability in Hdh CAG knock-in mice reveals different expansion dynamics in striatum and liver. PLoS ONE 6:e23647.
27. Liao DJ, Du Q, Yu BW, Grignon D, Sarkar FH. 2008. Novel perspective: focusing on the X chromosome in reproductive cancers. Cancer Invest 21:641-658.
28. Lin Y, Dion V, Wilson JH. 2006. Transcription promotes contraction of CAG repeat tracts in human cells. Nat Struct Mol Biol 13:179-180.
29. Lin Y, Hebert Jr. L, Wilson JH. 2009. Transcription destabilizes triplet repeats. Mol Carcinog 48:350-361.
30. Longo DL. 2012. Tumor heterogeneity and personalized medicine. N Engl J Med 366:956-957.
31. Lose F, Duffy DL, Kay GF, Kathleen Cunningham Foundation for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Management Group, Kedda MA, Spurdle AB. 2008. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. J Nat Cancer Inst 100:1519-1529.
32. Lyng MB, Lænkholm A-V, Pallisgaard N, Vach W, Knoop A, Bak M, Ditzel HJ. 2007. Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low-density array. Anal Cell Pathol 29:361-372.
33. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS, Chen YJ, Chen Z, Dewell SB, Du L, et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376-380.
34. Merlo LMF, Maley CC. 2010. The role of genetic diversity in cancer. J Clin Invest 120:401-403.
35. Mohamadi MR, Katakoa M, Mahmoudian L, Jabasini M, Shinohara Y, Baba Y. 2005. Analysis of sources of error in quantitation of purified DNA fragments and unpurified PCR products by DNA microchip electrophoresis. Chromatographia 61;339-344.
36. Narita D, Anghel A, Cimpean AM, Izvernariu D, Cireap N, Ilina R, Urosoniu S. 2010. Interaction between estrogens and androgen receptor genes microsatellites, prostate-specific antigen and androgen receptor expressions in breast cancer. Neoplasma 57:198-206.
37. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, Riggs M, Eberling Y, Troge J, Grubor V, Levy D, Lundin P, et al. 2010. Inferring tumor progression from genomic heterogeneity. Genome Res 20:68-80.
38. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. 2000. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 167:139-150.
39. Park SO, Gohen M, Kim, HJ, Michor F, Polyak K. 2010. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 120:636-644.
40. Park S, Koo J, Park HS, Kim J-H, Choi S-Y, Lee JH, Park BW, Lee KS. 2010. Expression of androgen receptors in primary breast cancer. Ann Oncol 21:488-492.
41. Qi J-P, Yang Y-L, Zhu H, Wang J, Jia Y, Liu N, Song Y-J, Zan L-K, Zhang X, Zhou M, Gu Y-H, Liu T, et al. 2012. Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients. Breast Cancer: Basic Clin Res 6:1-6.
42. Russnes HG, Navin N, Hicks J, Borresen-Dale A-L. 2011. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 121:3810-3818.
43. Shibata D. 2012. Heterogeneity and tumor history. Science 336:304-305.
44. Sircar K, Gottlieb B, Alvarado C, Aprikian A, Beitel LK, Alam-Fahmy M, Begin L, Trifiro M. 2007. Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer Prostatic Dis 10:360-386.
45. Stratton MR. 2011. Exploring the genomes of cancer cells: progress and promise. Science 331:1553-1558.
46. Swami M, Hendricks AE, Gillis T, Massood T, Mysore J, Myers RH, Wheeler VC. 2009. Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet 18:3039-3047.
47. Swanton C, Burrell RA, Futreal PA. 2011. Breast cancer genome heterogeneity: a challenge to personalised medicine? Breast Cancer Res 13:104-105.
48. The Thousand Genomes Project Consortium. 2010. A map of human genome variation from population-scale sequencing. Nature 467:1061-1073.
49. Varley KE, Mutch DG, Edmonston TB, Goodfellow PJ, Mitra RD. 2009. Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acid Res 37:4603-4612.
50. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17:1195-1201.
51. Yap TA, Gerlinger M, Futreal RA, Pusztal L, Swanton C. 2012. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4:127ps10.